Baricitinib for Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 2018;392:222–31
This international Phase 2 study aimed to assess the efficacy and safety of baricitinib, an oral JAK-1 and -2 inhibitor, in patients with SLE who were not adequately controlled despite standard background therapy.
Wallace et al found that 4 mg baricitinib significantly improved signs and symptoms of SLE, measured by resolution of arthritis or rash as defined by SLEDAI-2K. The safety profile of baricitinib was consistent with previous studies.